ACS Omega (Sep 2017)
In Vitro Evaluation of Novel Nitazoxanide Derivatives against Mycobacterium tuberculosis
- Joshua Odingo,
- Mai A. Bailey,
- Megan Files,
- Julie V. Early,
- Torey Alling,
- Devon Dennison,
- Julie Bowman,
- Suryakanta Dalai,
- Naresh Kumar,
- Jeffrey Cramer,
- Thierry Masquelin,
- Philip A. Hipskind,
- Tanya Parish
Affiliations
- Joshua Odingo
- Infectious Disease Research Institute, TB Discovery Research, Seattle, Washington, United States
- Mai A. Bailey
- Infectious Disease Research Institute, TB Discovery Research, Seattle, Washington, United States
- Megan Files
- Infectious Disease Research Institute, TB Discovery Research, Seattle, Washington, United States
- Julie V. Early
- Infectious Disease Research Institute, TB Discovery Research, Seattle, Washington, United States
- Torey Alling
- Infectious Disease Research Institute, TB Discovery Research, Seattle, Washington, United States
- Devon Dennison
- Infectious Disease Research Institute, TB Discovery Research, Seattle, Washington, United States
- Julie Bowman
- Infectious Disease Research Institute, TB Discovery Research, Seattle, Washington, United States
- Suryakanta Dalai
- Jubilant Chemsys Limited, Noida, India
- Naresh Kumar
- Jubilant Chemsys Limited, Noida, India
- Jeffrey Cramer
- Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana, United States
- Thierry Masquelin
- Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana, United States
- Philip A. Hipskind
- Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana, United States
- Tanya Parish
- Infectious Disease Research Institute, TB Discovery Research, Seattle, Washington, United States
- DOI
- https://doi.org/10.1021/acsomega.7b00892
- Journal volume & issue
-
Vol. 2,
no. 9
pp. 5873 – 5890
Abstract
No abstracts available.
